Targeted Shroom3-Rock interaction to reduce kidney scarring in CKD
Official title: Cell-type specific inhibition of Shroom3-Rock interaction to mitigate progressive tubulointerstitial fibrosis
Funded at Yale University · NIH-11459312 · Data updated 2026-11-12
Aims to block a specific protein interaction in people with chronic kidney disease to prevent scarring and loss of kidney function.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project start | September 10, 2019 |
| Project end | May 31, 2030 |
| Funding year | 2026 |
| Award (this year) | $828,500 |
| NIH project number | 2R01DK122164-06A1 |
| Project ID | NIH-11459312 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with chronic kidney disease or risk factors for CKD who have Shroom3-related pathways involved in their disease.
✕Less likely to help
People whose CKD is not driven by Shroom3 signaling or who have advanced disease where fibrosis is irreversible may not benefit.
What this research studies
This project focuses on understanding how Shroom3 and Rock interact in kidney cells and whether interrupting this interaction can reduce tubulointerstitial fibrosis, a key driver of CKD progression. Researchers will study how Shroom3 variants found in people with CKD affect signaling pathways and kidney cell behavior, using models that reflect human disease. The goal is to identify a precise intervention that can lower harmful signaling and protect kidney structure, with potential steps toward translating findings into human therapies.
Why it matters
Potential benefit: If successful, the work could lead to a treatment that slows or prevents kidney scarring in CKD patients.
How similar studies have gone: Prior work has identified Shroom3 domains affecting signaling and fibrosis, suggesting a plausible path toward a targeted therapy.
Where this research is happening
-
Yale University
New Haven, United States Active
Researchers
- Principal investigator: Menon, Madhav C — Yale University
- Study coordinator: Menon, Madhav C
Related research
Other NIH-funded projects on the same topics.
-
Interface between immune cells and scarring in the eye
This grant looks at how immune cells influence scar formation in the cornea after injury and how this affects vision.
-
How often to treat schistosomiasis to protect the liver
A randomized trial will test different frequencies ofPraziquantel treatment to prevent liver damage in people aged 15–40 with schistosomiasis in Uganda.
-
Metabolic changes in cells that repair blood vessels in the eye lens to prevent scarring
A drug or approach that changes how certain cells that repair blood vessels in the eye work, to prevent scarring behind the retina in age-related macular degeneration patients treated with anti-VEGF therapy.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This project studies heart tissue changes in women with HIV in sub-Saharan Africa who are on antiretroviral therapy, to understand why they’re at higher risk for heart problems as they age.
-
Myocardial fibrosis and fat in ART-treated women with HIV in sub-Saharan Africa
This grant studies heart tissue changes in women living with HIV in sub-Saharan Africa to understand why heart failure risk is higher in this group.
-
Molecular clues to progressive lung scarring
Researchers are studying how lung tissue becomes progressively scarred, focusing on cell signals and receptors that may drive fibrosis in people with lung disease.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.